Camizestrant vs Imlunestrant
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HR+/HER2- Metastatic Breast Cancer
Shared mechanism: Estrogen receptor · full HR+/HER2- Metastatic Breast Cancer pipeline
Camizestrant · Etcamah
Marketed by AstraZeneca
NCT04964934 · Phase 3 · active, not recruiting
This was a randomized, triple-blinded, placebo-controlled Phase III trial with an active comparator (continued aromatase inhibitor) in 315 patients, using progression-free survival (a hard clinical endpoint) as the primary measure. The result, reported via an external source since CT.gov has not yet posted results, showed a clear and highly statistically significant benefit for camizestrant (median PFS 16.0 vs 9.2 months, HR 0.44, p<0.00001), meeting the primary endpoint in the favorable direction.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: May 2027 · NCT04644068 (registry estimate)
Reported efficacy
Progression-free survival (PFS) assessed by the Investigator as defined by response evaluation criteria in solid tumors (RECIST version 1.1) (From randomization until the earlier of the progression event or death (approximately 2 years)): SERENA-6 (NCT04964934), primary endpoint PFS: median PFS 16.0 months (camizestrant + CDK4/6i) vs 9.2 months (aromatase inhibitor + CDK4/6i); HR 0.44 (95% CI 0.31-0.60); p<0.00001 (met)
Result source: NCT04964934
Imlunestrant · Inluriyo
Marketed by Eli Lilly
NCT04975308 · Phase 3 · active, not recruiting
EMBER-3 randomised 874 patients with ER-positive, HER2-negative advanced breast cancer in an open-label design, with three registered primary PFS comparisons. Imlunestrant beat standard endocrine therapy in patients with ESR1 mutations (HR 0.617, p=0.0008) but not in all patients (HR 0.867, p=0.1158), and the combination with abemaciclib beat imlunestrant alone (HR 0.569, p<0.0001). The result is mixed across the primaries and the open-label design keeps the grade at moderate.
Next expected readout: October 2028 · NCT07905001 (registry estimate)
Reported efficacy
Investigator-assessed Progression Free Survival (PFS) (Between Arm A and Arm B) (Randomization to the date of first documented progression of disease or death from any cause (up to 28 months)); Investigator-assessed PFS (Between Arm C and Arm A) (Randomization to the date of first documented progression of disease or death from any cause (up to 26 months)); Investigator-assessed PFS in the Estrogen Receptor 1 (ESR1)-Mutation Detected Population (Between Arm A and Arm B) (Randomization to the date of first documented progression of disease or death from any cause (up to 28 months)): Investigator-assessed PFS. ESR1-mutated population: imlunestrant 5.49 vs 3.84 months with standard endocrine therapy, HR 0.617 (95% CI 0.464 to 0.821), p=0.0008. All patients: 5.55 vs 5.52 months, HR 0.867 (95% CI 0.724 to 1.039), p=0.1158 (not significant). Imlunestrant plus abemaciclib vs imlunestrant: 9.36 vs 5.49 months, HR 0.569 (95% CI 0.441 to 0.733), p<0.0001 (mixed)
Result source: NCT04975308
Results for HR+/HER2- Metastatic Breast Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Camizestrant | Imlunestrant |
|---|---|---|
| PFS, median | —Trial running · NCT07717450 | 5.5 vs 5.5vs Investigator's Choice of Endocrine TherapyNCT049753087 other results
|
| OS, median | —Trial running · NCT07717450 | —Trial running · NCT04975308 |
| ORR | —Trial running · NCT07717450 | 10.3% vs 6.4%vs Investigator's Choice of Endocrine TherapyNCT049753083 other results
|
| Clinical benefit rate | —Trial running · NCT07717450 | 46.8% vs 45.5%vs Investigator's Choice of Endocrine TherapyNCT049753083 other results
|
PFS, median
- Camizestrant
- —Trial running · NCT07717450
- Imlunestrant
- 5.5 vs 5.5vs Investigator's Choice of Endocrine TherapyNCT04975308
7 other results
- 5.5 vs 3.8 NCT04975308
- 9.4 NCT04975308
- 5.5 NCT04975308
- 9.2 vs 7.4 NCT04975308
- 7.4 vs 5.5 NCT04975308
- 14.5 NCT04975308
- 9.2 NCT04975308
OS, median
- Camizestrant
- —Trial running · NCT07717450
- Imlunestrant
- —Trial running · NCT04975308
ORR
- Camizestrant
- —Trial running · NCT07717450
- Imlunestrant
- 10.3% vs 6.4%vs Investigator's Choice of Endocrine TherapyNCT04975308
3 other results
- 11.6% vs 5.9% NCT04975308
- 21.1% NCT04975308
- 9.4% NCT04975308
Clinical benefit rate
- Camizestrant
- —Trial running · NCT07717450
- Imlunestrant
- 46.8% vs 45.5%vs Investigator's Choice of Endocrine TherapyNCT04975308
3 other results
- 46.4% vs 36.4% NCT04975308
- 62.9% NCT04975308
- 44.1% NCT04975308
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Camizestrant: 4 of 4 rows · Imlunestrant: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Camizestrant | Imlunestrant |
|---|---|---|
| Dropout rate | 3.3%75 mga NCT04588298 · Phase 2 show 4 more results3.3%75 mg NCT04588298 · Phase 2 7.7%300 mg NCT04588298 · Phase 2 0%150 mg NCT04588298 · Phase 2 6.9%150 mg NCT04588298 · Phase 2 | 25.7%Arm A: Imlunestrant NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 1 more result45.1%Arm C: Imlunestrant + Abemaciclib NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 |
| Discontinued due to AEs | 0%75 mga NCT04588298 · Phase 2 show 4 more results0%75 mg NCT04588298 · Phase 2 7.7%300 mg NCT04588298 · Phase 2 0%150 mg NCT04588298 · Phase 2 6.9%150 mg NCT04588298 · Phase 2 | 3%Arm A: Imlunestrant NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 1 more result5.6%Arm C: Imlunestrant + Abemaciclib NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 |
| Serious AEs | 0%75 mga NCT04588298 · Phase 2 show 4 more results0%75 mg NCT04588298 · Phase 2 0%300 mg NCT04588298 · Phase 2 0%150 mg NCT04588298 · Phase 2 0%150 mg NCT04588298 · Phase 2 | 14.1%Arm A: Imlunestrant NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 1 more result20.2%Arm C: Imlunestrant + Abemaciclib NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 |
| Most frequent reported AEs | show 4 more results | diarrhoea 21.7% nausea 18% arthralgia 15.3% NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 1 more resultdiarrhoea 86.5% nausea 50% anaemia 43.8% NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Imlunestrant
show 3 more results
show 3 more results
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
Breast Cancer
Shared mechanism: Estrogen receptor · full Breast Cancer pipeline
Camizestrant · Etcamah
Marketed by AstraZeneca
NCT04964934 · Phase 3 · active, not recruiting
This was a randomized, triple-blinded, placebo-controlled Phase III trial with an active comparator (continued aromatase inhibitor) in 315 patients, using progression-free survival (a hard clinical endpoint) as the primary measure. The result, reported via an external source since CT.gov has not yet posted results, showed a clear and highly statistically significant benefit for camizestrant (median PFS 16.0 vs 9.2 months, HR 0.44, p<0.00001), meeting the primary endpoint in the favorable direction.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: April 2027 · NCT05774951 (registry estimate)
Reported efficacy
Progression-free survival (PFS) assessed by the Investigator as defined by response evaluation criteria in solid tumors (RECIST version 1.1) (From randomization until the earlier of the progression event or death (approximately 2 years)): SERENA-6 (NCT04964934), primary endpoint PFS: median PFS 16.0 months (camizestrant + CDK4/6i) vs 9.2 months (aromatase inhibitor + CDK4/6i); HR 0.44 (95% CI 0.31-0.60); p<0.00001 (met)
Result source: NCT04964934
Imlunestrant · Inluriyo
Marketed by Eli Lilly
NCT04975308 · Phase 3 · active, not recruiting
EMBER-3 randomised 874 patients with ER-positive, HER2-negative advanced breast cancer in an open-label design, with three registered primary PFS comparisons. Imlunestrant beat standard endocrine therapy in patients with ESR1 mutations (HR 0.617, p=0.0008) but not in all patients (HR 0.867, p=0.1158), and the combination with abemaciclib beat imlunestrant alone (HR 0.569, p<0.0001). The result is mixed across the primaries and the open-label design keeps the grade at moderate.
Next expected readout: October 2027 · NCT05514054 (registry estimate)
Reported efficacy
Investigator-assessed Progression Free Survival (PFS) (Between Arm A and Arm B) (Randomization to the date of first documented progression of disease or death from any cause (up to 28 months)); Investigator-assessed PFS (Between Arm C and Arm A) (Randomization to the date of first documented progression of disease or death from any cause (up to 26 months)); Investigator-assessed PFS in the Estrogen Receptor 1 (ESR1)-Mutation Detected Population (Between Arm A and Arm B) (Randomization to the date of first documented progression of disease or death from any cause (up to 28 months)): Investigator-assessed PFS. ESR1-mutated population: imlunestrant 5.49 vs 3.84 months with standard endocrine therapy, HR 0.617 (95% CI 0.464 to 0.821), p=0.0008. All patients: 5.55 vs 5.52 months, HR 0.867 (95% CI 0.724 to 1.039), p=0.1158 (not significant). Imlunestrant plus abemaciclib vs imlunestrant: 9.36 vs 5.49 months, HR 0.569 (95% CI 0.441 to 0.733), p<0.0001 (mixed)
Result source: NCT04975308
Results for Breast Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
Coverage. Camizestrant: 4 of 4 rows · Imlunestrant: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Camizestrant | Imlunestrant |
|---|---|---|
| Dropout rate | 3.3%75 mga NCT04588298 · Phase 2 show 4 more results3.3%75 mg NCT04588298 · Phase 2 7.7%300 mg NCT04588298 · Phase 2 0%150 mg NCT04588298 · Phase 2 6.9%150 mg NCT04588298 · Phase 2 | 25.7%Arm A: Imlunestrant NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 1 more result45.1%Arm C: Imlunestrant + Abemaciclib NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 |
| Discontinued due to AEs | 0%75 mga NCT04588298 · Phase 2 show 4 more results0%75 mg NCT04588298 · Phase 2 7.7%300 mg NCT04588298 · Phase 2 0%150 mg NCT04588298 · Phase 2 6.9%150 mg NCT04588298 · Phase 2 | 3%Arm A: Imlunestrant NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 1 more result5.6%Arm C: Imlunestrant + Abemaciclib NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 |
| Serious AEs | 0%75 mga NCT04588298 · Phase 2 show 4 more results0%75 mg NCT04588298 · Phase 2 0%300 mg NCT04588298 · Phase 2 0%150 mg NCT04588298 · Phase 2 0%150 mg NCT04588298 · Phase 2 | 14.1%Arm A: Imlunestrant NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 1 more result20.2%Arm C: Imlunestrant + Abemaciclib NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 |
| Most frequent reported AEs | show 4 more results | diarrhoea 21.7% nausea 18% arthralgia 15.3% NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 1 more resultdiarrhoea 86.5% nausea 50% anaemia 43.8% NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Imlunestrant
show 3 more results
show 3 more results
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Camizestrant's landscape · Imlunestrant's landscape